Core Viewpoint - Nanwei Technology expects a significant increase in net profit for 2025, projecting a growth of 54.51% to 75.03% year-on-year, driven by strategic market development and product innovation [1] Financial Performance - The company forecasts a net profit attributable to shareholders of 128 million to 145 million yuan for 2025 [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 112 million and 128 million yuan, reflecting a year-on-year increase of 70.02% to 94.31% [1] Business Strategy - The company is implementing a "3+2" market development strategy focusing on three key sectors: peptides, bispecific antibodies/ADC, and blood products, while also exploring growth opportunities in vaccines and small nucleic acids [1] - The strategy aims to enhance competitive advantages through technological innovation of key products and quality improvements [1] Sales Growth - Sales revenue from core products, including chromatographic fillers and chromatography media, has increased by approximately 23% this year [1] - Sales revenue from liquid chromatography columns and sample preparation products has seen a growth of about 32% [1] International Expansion - The company is intensifying efforts to expand into international markets, enhancing its overseas marketing system and strengthening sales capabilities [1] - International business revenue reached approximately 84 million yuan, marking a year-on-year increase of about 79% [1]
纳微科技:2025年全年净利润同比预增54.51%—75.03%